FN-1501

Generic Name
FN-1501
Brand Names
Cellcept, Myfenax, CellCept, Mycophenolate mofetil Teva, Myclausen
Drug Type
Small Molecule
Chemical Formula
C22H25N9O
CAS Number
1429515-59-2
Unique Ingredient Identifier
6MC966B505
Background

Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as Cyclosporine and corticosteroids to prevent organ rejection after hepatic, renal, and cardiac transplants. It is markete...

Indication

Mycophenolate mofetil is indicated in combination with other immunosuppressants to prevent the rejection of kidney, heart, or liver transplants in adult and pediatric patients ≥3 months old. Mycophenolate mofetil may also be used off-label as a second-line treatment for autoimmune hepatitis that has not responded adequately to first-line therapy. Other off-l...

Associated Conditions
Transplanted Organ Rejection
Associated Therapies
-
Clinical Trials
Related News

Haplo Peripheral Blood Sct In GVHD Prevention

First Posted Date
2020-07-16
Last Posted Date
2024-03-07
Lead Sponsor
Zachariah Michael DeFilipp
Target Recruit Count
25
Registration Number
NCT04473911
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk

First Posted Date
2020-07-16
Last Posted Date
2022-05-06
Lead Sponsor
University of California, San Francisco
Registration Number
NCT04473924
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

Efficacy of Anti-CD20 Antibodies (Rituximab Biosimilar) in the Treatment of Childhood Steroid-dependent Nephrotic Syndrome

First Posted Date
2020-05-27
Last Posted Date
2020-09-14
Lead Sponsor
Istituto Giannina Gaslini
Target Recruit Count
30
Registration Number
NCT04402580
Locations
🇮🇹

IRCCS Istituto Giannina Gaslini, Genova, Italy

Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis

First Posted Date
2020-05-12
Last Posted Date
2024-10-17
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
45
Registration Number
NCT04384692
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy

First Posted Date
2020-05-06
Last Posted Date
2021-06-22
Lead Sponsor
West China Hospital
Target Recruit Count
89
Registration Number
NCT04376528
Locations
🇨🇳

WestChina Hospital, Chengdu, Sichuan, China

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Phase 1
Recruiting
Conditions
Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory Chronic Myelomonocytic Leukemia
Refractory Mixed Phenotype Acute Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Myelodysplastic Syndrome
Refractory Acute Leukemia of Ambiguous Lineage
Refractory Acute Undifferentiated Leukemia
Interventions
Drug: Cyclophosphamide
Drug: Cladribine
Drug: Cyclosporine
Drug: Cytarabine
Biological: Filgrastim
Procedure: Hematopoietic Cell Transplantation
Drug: Mitoxantrone
Drug: Idarubicin
Drug: Mycophenolate Mofetil
Drug: Fludarabine
Drug: Mycophenolate Sodium
Radiation: Total-Body Irradiation
Procedure: Multigated Acquisition Scan
Procedure: Echocardiography
Procedure: X-Ray Imaging
Procedure: Bone Marrow Biopsy
Procedure: Bone Marrow Aspiration
Procedure: Biospecimen Collection
First Posted Date
2020-05-05
Last Posted Date
2024-11-04
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
120
Registration Number
NCT04375631
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

First Posted Date
2020-04-30
Last Posted Date
2024-07-11
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
20
Registration Number
NCT04370301
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia

First Posted Date
2020-02-10
Last Posted Date
2024-03-06
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
70
Registration Number
NCT04262843
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide

First Posted Date
2020-01-18
Last Posted Date
2024-12-06
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
27
Registration Number
NCT04232085
Locations
🇺🇸

Johns Hopkins University, Baltimore, Maryland, United States

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

First Posted Date
2020-01-07
Last Posted Date
2024-01-12
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT04220008
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy